Germline EPHB2 receptor variants in familial colorectal cancer

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  Zogopoulos, George ^a   Jorgensen, Claus ^a   Bacani, Julinor ^a   Montpetit, Alexandre ^b   Lepage, Pierre ^b   Ferretti, Vincent ^b   Chad, Lauren ^b   Selvarajah, Subani ^a   Zanke, Brent ^c,d   Hudson, Thomas J ^c,d   Pawson, Tony ^a   Gallinger, Steven ^a,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CANCER CARE ONTARIO   (Canada)

^d ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR B2; DNA;

ADULT; AGED; ARTICLE; CARBOXY TERMINAL SEQUENCE; COLORECTAL CANCER; CONTROLLED STUDY; DNA SEQUENCE; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; POPULATION BASED CASE CONTROL STUDY; POPULATION GENETICS; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE; WILD TYPE; COLON POLYPOSIS; COLORECTAL TUMOR; EXON; GENETICS; ISOLATION AND PURIFICATION; MUTATION; PEDIGREE; REFERENCE VALUE; REGISTER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOMATOUS POLYPOSIS COLI; BASE SEQUENCE; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA, NEOPLASM; EXONS; FEMALE; GENETIC VARIATION; GERM-LINE MUTATION; HUMANS; MALE; PEDIGREE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPHB2; REFERENCE VALUES; REGISTRIES;

EID: 51449099398     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002885     Document Type: Article

References (24)

1. de la Chapelle A (2004) Genetic predisposition to colorectal cancer. Nat Rev Cancer 4: 769-780.
2. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, et al. (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237.
3. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW (1998) Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58: 1130-1134.
4. Shitoh K, Furukawa T, Kojima M, Konishi F, Miyaki M, et al. (2001) Frequent activation of the beta-catenin-Tcf signaling pathway in nonfamilial colorectal carcinomas with microsatellite instability. Genes Chromosomes Cancer 30: 32-37.
5. Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, et al. (2002) Beta-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell 111: 251-263.
6. Clevers H, Batlle E (2006) EphB/EphrinB receptors and Wnt signaling in colorectal cancer. Cancer Res 66: 2-5.
7. Praml C, Finke LH, Herfarth C, Schlag P, Schwab M, et al. (1995) Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer. Oncogene 11: 1357-1362.
8. Ogunbiyi OA, Goodfellow PJ, Gagliardi G, Swanson PE, Birnbaum EH, et al. (1997) Prognostic value of chromosome 1p allelic loss in colon cancer. Gastroenterology 113: 76176-76186.
9. Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, et al. (2005) Mechanisms or inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65: 10170-10173.
10. Jubb AM, Zhong F, Bheddah S, Grabsch HI, Frantz GD, et al. (2005) EphB2 is a prognostic factor in colorectal cancer. Clin Cancer Res 11: 5181-5187.
11. Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, et al. (2004) Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36: 979-983.
12. Kittles RA, Baffoe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, et al. (2006) A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 43: 507-511.
13. Cotterchio M, McKeown-Eyssen G, Sutherland H, Buchan G, Aronson M, et al. (2000) Ontario familial colon cancer registry: methods and first-year response rates. Chronic Dis Can 21: 81-86.
14. Mira MT, Alcaïs A, Thuc NV, Moraes MO, Di Flumeri G, et al. (2004) Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 427: 636-640.
15. Henkemeyer M, Marengere LE, McGlade J, Olivier JP, Conlon RA, et al. (1994) Immunolocalization of the Nuk receptor tyrosine kinase suggests roles in segmental patterning of the brain and axonogenesis. Oncogene 9: 1001-1014.
16. Holland SJ, Gale NW, Gish GD, Roth RA, Songyang Z, et al. (1997) Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J 16: 3877-3888.
17. Skorstengaard K, Jensen MS, Sahl P, Petersen TE, Magnusson S (1986) Complete primary structure of bovine plasma fibronectin. Eur J Biochem 161: 441-453.
18. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, et al. (2001) Structural basis for autoinhibition or the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106: 745-757.
19. Pasquale EB (2005) Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol 6: 462-475.
20. Aasheim HC, Patzke S, Hjorthaug HS, Finne EF (2005) Characterization of a novel Eph receptor tyrosine kinase, EphA10, expressed in testis. Journal Biochim Biophys Acta 1723: 1-7.
21. Holmberg J, Genander M, Halford MM, Anneren C, Sondell M, et al. (2006) EphB receptors coordinate migration and proliferation in the intestinal stem cell niche. Cell 125: 1151-1163.
22. Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, et al. (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 135: 1126-1130.
23. Oba SM, Wang YJ, Song JP, Li ZY, Kobayashi K, et al. (2001) Genomic structure and loss of heterozygosity of EPHB2 in colorectal cancer. Cancer Lett 164: 97-104.
24. Kokko A, Laiho P, Lehtonen R, Korja S, Carvajal-Carmona LG, et al. (2006) EPHB2 germline variants in patients with colorectal cancer or hyperplastic polyposis. BMC Cancer 6: 145.